No Data
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Guangzhou Baiyunshan Pharma Gets Local Approval to Reduce, Add Production Lines
BAIYUNSHAN PH (00874): Zhongyi Pharmaceutical's change of the Pharmaceutical Production License.
BAIYUNSHAN PH (00874) released an announcement that recently, the company's wholly-owned subsidiary Guangzhou BAIYUNSHAN PH Zhongyi Pharmaceutical Co., Ltd. (referred to as...
BAIYUNSHAN PH (600332.SH): Subsidiary received the pharmaceutical registration certificate from Macau.
On January 9, Gelonghui announced that BAIYUNSHAN PH (600332.SH) reported that its holding subsidiary, Guangzhou BAIYUNSHAN Guanghua Pharmaceutical Co., Ltd., received the "Chinese Patent Medicine Registration Certificate" issued by the Macao Special Administrative Region's Drug Administration, with the product names: Xiao Chai Hu Granules (sugar-free type) [BAIYUNSHAN], Xiao Chai Hu Granules [BAIYUNSHAN]. The functions and indications of Xiao Chai Hu Granules are to release the exterior, disperse heat, and soothe the liver and stomach. It is used for external contraction diseases, with pathogenic factors invading the Shaoyang syndrome, symptoms include alternating chills and fever, fullness in the chest and hypochondria, loss of appetite, irritability with a tendency to vomit, and bitter taste in the mouth with dryness in the throat.
BAIYUNSHAN PH (600332.SH): The BYS30 particles have received the drug clinical trial approval notification.
On January 9, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its subsidiary, Guangzhou BAIYUNSHAN Pharmaceutical Group Co., Ltd., received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration for the drug named: BYS30 Granules. BYS30 Granules is a Class 1 innovative Traditional Chinese Medicine compound formulation developed by the BAIYUNSHAN Pharmaceutical Factory, indicated for knee osteoarthritis.
BAIYUNSHAN PH (600332.SH): LBZ-18 and LBZ-18 oral emulsion have received the clinical trial approval notice.
On January 9, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its subsidiary, Guangzhou BAIYUNSHAN Hanfang Modern Pharmaceutical Co., Ltd., received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration, with the drug names: LBZ-18 and LBZ-18 Oral Emulsion. LBZ-18 Oral Emulsion is an Innovative Drug of Category I Traditional Chinese Medicine independently developed by BAIYUNSHAN Hanfang, indicated for invigorating qi and strengthening the spleen, used for the treatment of cancer-related fatigue in tumor patients.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
